You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for FIBER LAXATIVE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for FIBER LAXATIVE

Average Pharmacy Cost for FIBER LAXATIVE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
FIBER LAXATIVE 625 MG CAPLET 70000-0067-01 0.05902 EACH 2026-03-18
FIBER LAXATIVE 625 MG CAPLET 70000-0067-01 0.06056 EACH 2026-02-18
FIBER LAXATIVE 625 MG CAPLET 70000-0067-01 0.06166 EACH 2026-01-21
FIBER LAXATIVE 625 MG CAPLET 70000-0067-01 0.05980 EACH 2025-12-17
FIBER LAXATIVE 625 MG CAPLET 70000-0067-01 0.05872 EACH 2025-11-19
>Drug Name >NDC >Price/Unit ($) >Unit >Date

FIBER LAXATIVE Market Analysis and Financial Projection

Last updated: February 17, 2026

Market Overview of Fiber Laxatives

The global fiber laxative market is driven by increasing prevalence of constipation, dietary fiber awareness, and aging populations. It is segmented into bulk-forming, docusate-based, and other fiber laxatives. The market experienced steady growth, reaching an estimated USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of approximately 5% from 2023 to 2030, reaching USD 1.9 billion by 2030.

Key Drivers

  • Rising prevalence of gastrointestinal disorders.
  • Increased consumer awareness of dietary fiber benefits.
  • Growing elderly population with chronic constipation.
  • Expansion in emerging markets.

Market Segments

Segment 2022 Market Share Main Brands Growth Drivers
Bulk-forming 60% Metamucil, FiberCon, Konsyl Long-standing efficacy, OTC availability
Docusate-based 25% Colace, Ducodyl Prescription and OTC use, mild safety profile
Others 15% Psyllium husk, methylcellulose Natural options, consumer preference for plant-based fibers

Competitive Landscape

Major pharmaceutical and OTC companies hold significant market share:

  • Procter & Gamble (Metamucil)
  • Johnson & Johnson (Ducodyl)
  • private-label brands gaining ground in retail markets

Recent industry shifts include:

  • Introduction of fiber products with added probiotics.
  • Growing consumer trend toward natural and plant-based ingredients.
  • Strategic alliances and acquisitions to expand distribution.

Price Projections and Trends

Historical Pricing (2022)

  • Bulk-forming fiber laxatives: USD 10-15 per 30-day supply.
  • Docusate-based products: USD 8-12 per 30-day supply.
  • Natural fiber supplements: USD 12-20 per 30-day supply.

Expected Price Trends (2023-2030)

  • Moderate price increases of 2-3% annually, driven by raw material costs and regulatory compliance.
  • Natural and plant-based fiber products may command premiums of 10-15% over traditional formulations due to consumer demand.
  • Private-label brands may maintain lower price points, inhibiting price inflation for premium products.

Regional Variations

Region Price Range (USD) per 30-day supply Market Dynamics
North America 10-20 High consumer awareness, brand dominance
Europe 8-18 Stringent regulations, preference for natural ingredients
Asia-Pacific 5-12 Growing market, price sensitivity

Regulatory and Market Access

Regulatory approvals for fiber laxatives are generally straightforward due to OTC status in many markets. FDA regulates formulations in the U.S., with monographs covering bulk-forming agents. European Medicines Agency (EMA) and other regional agencies enforce safety standards.

Market entry often depends on:

  • Composition compliance.
  • Evidence of safety and efficacy.
  • Marketing claims adherence.

Opportunities and Risks

Opportunities

  • Expansion into emerging markets through affordable formulations.
  • Innovation in delivery formats (e.g., powders, chewables).
  • Incorporation of prebiotics or probiotics to differentiate offerings.

Risks

  • Market saturation in developed nations.
  • Regulatory changes affecting OTC classification.
  • Consumer shift toward alternative gastrointestinal health products.

Key Takeaways

  • The fiber laxative market is expected to grow steadily, reaching USD 1.9 billion by 2030.
  • Price stability prevails with minor annual increases; premium natural products may cost more.
  • Dominance by established brands like Metamucil and Colace remains, but private-label growth persists.
  • Market expansion hinges on product innovation, natural ingredient trends, and geographic diversification.
  • Regulatory environments favor OTC formulations, with potential hurdles in emerging markets.

FAQs

1. What are the main forms of fiber laxatives available?
Bulk-forming, docusate-based, and natural fiber supplements dominate the market.

2. How are prices expected to change in the next five years?
Prices are projected to increase by 2-3% annually, with natural and premium formulations slightly higher.

3. Which regions offer the most growth opportunities?
Emerging markets in Asia-Pacific and Latin America present significant growth potential.

4. What factors influence fiber laxative pricing?
Raw material costs, formulation complexity, regulatory compliance, and brand positioning.

5. Are natural fiber laxatives more expensive?
Generally, yes; natural and plant-based fiber products tend to carry a premium due to consumer preference and ingredient sourcing.


References

  1. MarketWatch, "Global Fiber Laxative Market Size," 2022.
  2. Grand View Research, "Constipation Treatment Market Forecast," 2023.
  3. U.S. Food and Drug Administration, OTC Monographs, 2022.
  4. European Medicines Agency, Guidelines on Gastrointestinal Products, 2022.
  5. IQVIA, "Pharmaceutical Market Trends," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.